论文部分内容阅读
我国是乙型病毒性肝炎的高发国家 ,约有 1.2亿的HBV携带者 ,而原发性肝癌中 90 %的患者有HBV感染[1] 。研究者发现 ,72 .7%的肝癌癌旁组织及 4 5 %的肝癌组织中可检出HBsAg,故其可作为肝炎后肝癌患者免疫治疗的相对特异的“肿瘤相关分子”[2 ] 。如果能将HBsAg附加到来源于肝癌
China is a high-incidence country with hepatitis B virus, with about 120 million HBV carriers, and about 90% of patients with primary liver cancer have HBV infection [1]. The researchers found that HBsAg can be detected in 72.7% of paracancerous tissues and 45% of hepatocellular carcinomas. Therefore, it can be used as a relatively specific “tumor-associated molecule” for immunotherapy of patients with post-hepatitis C liver cancer [2]. If you can attach HBsAg to liver cancer